Last reviewed · How we verify
Docetaxel, cisplatin and fluorouracil
This combination chemotherapy regimen uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis through different mechanisms.
This combination chemotherapy regimen uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis through different mechanisms. Used for Advanced gastric cancer, Head and neck cancer, Esophageal cancer.
At a glance
| Generic name | Docetaxel, cisplatin and fluorouracil |
|---|---|
| Also known as | TPF induction chemotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy (taxane + platinum + antimetabolite) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that stabilizes microtubules and prevents cell division; cisplatin is a platinum agent that cross-links DNA and causes strand breaks; and fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase and disrupts nucleotide synthesis. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Advanced gastric cancer
- Head and neck cancer
- Esophageal cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Mucositis
- Diarrhea
- Peripheral neuropathy
- Alopecia
- Fatigue
Key clinical trials
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer (PHASE2)
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE3)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (PHASE2)
- Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, cisplatin and fluorouracil CI brief — competitive landscape report
- Docetaxel, cisplatin and fluorouracil updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI